The sentinel lymph node biopsy for breast cancer over the years

The sentinel lymph node biopsy (SLNB) has progressively substituted complete axillary lymph node dissection (CALND), and has dramatically changed breast surgery impact on women's psychophysical wellness, reducing surgical morbidity while granting an adequate nodal staging. The present authors have seen a gradual improvement in the technique in order to reduce both surgical time and the number of interventions required, in particular with the intraoperative histological examination of sentinel node. Anyway, there is still great debate about the predictability of axillary nodal status in case of negative SLNB, as well as in case of positive one. Therefore, the authors reviewed the SLNB history and discussed its controversial points.

Sentinel lymph node biopsy; Complete axillary lymph node dissection; Breast cancer.

[1] Arnone P., Zurrida S., Viale G., Dellapasqua S., Montagna E., Arnaboldi P., et al.: “The TNM classification of breast cancer: need for change. Updates Surg., 2010, 62, 75.

[2] Veronesi U., Paganelli G., Galimberti V., Viale G., Zurrida S., Bedoni M., et al.: “Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes”. Lancet, 1997, 349, 1864.

[3] Johnson M.T., Guidroz J.A., Smith B.J., Graham M.M., Scott-Conner C.E.H., Sugg S.L., Weigel R.J.: “A single institutional experience of factors affecting successful identification of sentinel lymph node in breast cancer patients”. Surgery, 2009, 146, 671.

[4] Driul L., Bernardi S., Bertozzi S., Schiavon M., Londero A.P., Petri R.: “New surgical trends in breast cancer treatment: conservative interventions and oncoplastic breast surgery”. Minerva Ginecol., 2013, 65, 289.

[5] Cedolini C., Bertozzi S., Londero A.P., Bernardi S., Seriau L., Concina S., et al.: “Type of breast cancer diagnosis, screening, and survival”. Clin. Breast Cancer, 2014, 14, 235.

[6] Bertozzi S., Londero A.P., Petri R., Bernardi S.: “Isolated axillary nodal swelling and cancer of unknown primary”. Eur. J. Gynaec Oncol., 2015, 36, 131.

[7] Bernardi S., Bertozzi S., Londero A.P., Angione V., Petri R., Giacomuzzi F.: “Prevalence and risk factors of intraoperative identification failure of sentinel lymph nodes in patients affected by breast cancer”. Nucl. Med. Commun., 2013, 34, 664.

[8] Jung S.Y., Kim S.K., Kim S.W., Kwon Y., Lee E.S., Kang H.S., et al.: “Comparison of Sentinel Lymph Node Biopsy Guided by the Multimodal Method of Indocyanine Green Fluorescence, Radioisotope, and Blue Dye Versus the Radioisotope Method in Breast Cancer: A Randomized Controlled Trial”. Ann. Surg. Oncol., 2013, 21, 1254. doi: 10.1245/s10434-013-3437-0. Epub 2013 Dec 20.

[9] Caruso G., Cipolla C., Costa R., Morabito A., Latteri S., Fricano S., et al.: “Lymphoscintigraphy with peritumoral injection versus lym-phoscintigraphy with subdermal periareolar injection of technetium-labeled human albumin to identify sentinel lymph nodes in breast cancer patients”. Acta Radiol., 2013, 55, 39. doi: 10.1177/ 0284185113493775. Epub 2013 Aug 7.

[10] McMasters K.M., Tuttle T.M., Carlson D.J., Brown C.M., Noyes

R.D., Glaser R.L., et al.: “Sentinel lymph node biopsy for breast cancer:

a suitable alternative to routine axillary dissection in multi-institutional

practice when optimal technique is used”. J. Clin. Oncol.,

2000, 18, 2560.

[11] McMasters K.M., Wong S.L., Chao C., Woo C., Tuttle T.M., Noyes

R.D., et al.: “Defining the optimal surgeon experience for breast cancer

sentinel lymph node biopsy: a model for implementation of new

surgical techniques”. Ann. Surg., 2001, 234, 292.

[12] Tanis P.J., van Sandick J.W., Nieweg O.E., Valdés Olmos R.A., Rutgers E.J.T., Hoefnagel C.A., Kroon B.B.R.: “The hidden sentinel node in breast cancer”. Eur. J. Nucl. Med. Mol. Imaging, 2002, 29, 305.

[13] Bertozzi S., Londero A.P., Giacomuzzi F., Angione V., Carbone A., Petri R., Bernardi S.: “Applicability of two different validated models to predict axillary non-sentinel lymph node status by sentinel node biopsy in a single Italian center”. Breast Cancer, 2013, Jul 6.[Epub ahead of print].

[14] Bernardi S., Bertozzi S., Londero A.P., Gentile G., Angione V., Petri R.: “Influence of surgical margins on the outcome of breast cancer patients: a retrospective analysis”. World J. Surg., 2014, 38, 2279.

[15] Bernardi S., Bertozzi S., Londero A.P., Gentile G., Giacomuzzi F., Carbone A.: “Incidence and risk factors of the intraoperative localization failure of nonpalpable breast lesions by radio-guided occult lesion localization: a retrospective analysis of 579 cases”. World J. Surg., 2012, 36, 1915.

[16] Cedolini C., Bertozzi S., Seriau L., Londero A.P., Concina S., Cattin F., et al.: “Eight-year experience with the intraoperative frozen section examination of sentinel lymph node biopsy for breast cancer in a North-Italian university center”. Int. J. Clin. Exp. Pathol., 2014, 7, 364.

[17] Cedolini C., Bertozzi S., Seriau L., Londero A.P., Concina S., Moretti E., et al.: “Feasibility of concervative breast surgery and intraoperative radiation therapy for early breast cancer: a single-center, open, non-randomized, prospective pilot study”. Oncol. Rep., 2014, 31, 1539.

[18] Fondazione Operativa Nazionale sul Carcinoma Mammario (FON-CaM). F.O.N.Ca.M.: “Linee guida. F.O.N.Ca.M., 2003”. (Update 2012). Available at: http://www.senologia.it/index.php/f-o-n-cam/linee-guida/25-foncam

[19] Associazione Italiana di Oncologia Medica (AIOM): “Linee guida: Neoplasie della mammella”. AIOM, 2013. Available at: http://www.aiom.it/area+pubblica/area+medica/prodotti+scien-tifici/linee+guida/1,333,1

[20] Lyman G.H., Temin S., Edge S.B., Newman L.A., Turner R.R., Weaver D.L., et al.: “Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.” J. Clin. Oncol., 2014, 32, 1365. doi: 10.1200/JCO.2013.54.1177. Epub 2014 Mar 24.

[21] National Institute for Health and Care Excellence (NICE): “Introperative tests (RD-100i OSNA system and Metasin test) for detection of sentinel lymph node metastses in breast cancer. NICE, 2013. Available at: http://www.nice.org.uk/guidance/dg8/resources/intraoperative-tests-rd100i-osna-system-and-metasin-test-for-detectingsentinel-lymph-node-metastases-in-breast-cancer-29279020741

[22] Intra M., Rotmensz N., Mattar D., Gentilini O.D., Vento A., Veronesi P., et al.: “Unnecessary axillary node dissections in the sentinel lymph node era”. Eur. J. Cancer, 2007, 43, 2664.

[23] Schem C., Maass N., Bauerschlag D.O., Carstensen M.H., Löning T., Roder C., et al.: “One-step nucleic acid amplification-a molecular method for the detection of lymph node metastases in breast cancer patients; results of the German study group”. Virchows Arch., 2009, 454, 203.

[24] Chaudhry A., Williams S., Cook J., Jenkins M., Sohail M., Calder C., et al.: “The real-time intra-operative evaluation of sentinel lymph nodes in breast cancer patients using One Step Nucleic Acid Ampli-fication (OSNA) and implications for clinical decision-making”. Eur. J. Surg. Oncol., 2014, 40, 150.

[25] Cattin F., Castriotta L., Zumerle G., Scarpa E., Leo C.A., Semprini G., et al.: “The breast cancer: a comparison among different diagnostic and therapeutic protocols”. Breast J., 2013, 19, 560.

[26] Ollila D.W., Carey L.A., Sartor C.I.: “Clinical significance of micrometastatic disease in the era of sentinel node”. Breast Dis., 2001, 12, 57.

[27] Riber-Hansen R., Nyengaard J.R., Hamilton-Dutoit S.J., Steiniche T.: “Stage migration after minor changes in histologic estimation of tumor burden in sentinel lymph nodes: the protocol trap”. Cancer, 2009, 115, 2177.